Literature DB >> 9740136

College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.

J D Olson1, C F Arkin, J T Brandt, M T Cunningham, A Giles, J A Koepke, D L Witte.   

Abstract

OBJECTIVE: To review the state of the art as reflected in the medical literature and the consensus opinion of recognized experts in the field regarding the laboratory monitoring of unfractionated heparin therapy. DATA SOURCES, EXTRACTION AND SYNTHESIS: The authors made an extensive review of the literature. The draft manuscript was circulated to every participant in the consensus conference prior to the convening of the conference. Extensive discussion concerning all of the issues addressed in the manuscript as well as the resulting recommendations occurred. This information was then used to revise the manuscript into its final form.
CONCLUSIONS: The resulting manuscript has 23 specific recommendations regarding preanalytic, analytic, and postanalytic phases of monitoring and testing for complications related to unfractionated heparin therapy. This report contains detailed discussion of these recommendations and includes literature citations that support them. A number of issues for which consensus could not be reached are also discussed. A method is provided to assist laboratories, particularly small laboratories, in providing clinicians with an appropriate therapeutic range for the activated partial thromboplastin time, the most commonly used test in monitoring heparin therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740136

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  28 in total

Review 1.  The role of point-of-care anticoagulation monitoring in arterial and venous thromboembolic disorders.

Authors:  C R Zimmerman
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

2.  Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels.

Authors:  Ramya Thota; Apar Kishor Ganti; Shanmuga Subbiah
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 3.  L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.

Authors:  Gaurav Goyal; Vijaya Raj Bhatt
Journal:  Future Oncol       Date:  2015-08-14       Impact factor: 3.404

Review 4.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.

Authors:  Leana Mahmoud; Andrew R Zullo; Donald McKaig; Christine M Berard-Collins
Journal:  R I Med J (2013)       Date:  2016-03-01

6.  Pulmonary embolism: current treatment options.

Authors:  Marc Meysman; Patrick Haentjens
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-12

Review 7.  Anticoagulant therapy in special circumstances.

Authors:  T G DeLoughery
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

8.  Comparison of Time to Therapeutic aPTT in Patients Who Received Continuous Unfractionated Heparin After Implementation of Pharmacy-wide Intervention Alerts.

Authors:  Duaa Alsulaiman; Katelyn Sylvester; Craig Stevens; Danielle Carter
Journal:  Hosp Pharm       Date:  2016-09

Review 9.  [Heparin resistance and antithrombin deficiency].

Authors:  Norbert Maurin
Journal:  Med Klin (Munich)       Date:  2009-06-16

10.  Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation.

Authors:  Melania M Bembea; Jamie M Schwartz; Nilay Shah; Elizabeth Colantuoni; Christoph U Lehmann; Thomas Kickler; Peter Pronovost; John J Strouse
Journal:  ASAIO J       Date:  2013 Jan-Feb       Impact factor: 2.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.